Hemoadsorption combined with hemodialysis versus hemodialysis alone on mortality in end-stage kidney disease: a randomized, open-label, multicenter trial - PubMed
7 hours ago
- #hemoadsorption
- #end-stage kidney disease
- #mortality
- HAHD combined with HD significantly reduced all-cause mortality (HR 0.778, P=0.045) in ESKD patients compared to HD alone.
- The HAHD group showed significant reductions in cardiovascular mortality (HR 0.659, P=0.009) and major cardiovascular events (HR 0.772, P=0.019).
- Adverse events like infections and abnormal blood pressure were comparable between HAHD and HD-only groups.
- Trial involved 1362 patients randomized 1:1, with median follow-up of 39.5 months across 11 centers in Shanghai.